A Study to Evaluate Safety, Tolerability and Efficacy of... | NCT03583944

Status Module

Label	Type	Description	Intervention Names
Eribulin Mesylate 1.23 mg	Experimental	Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.	Drug: Eribulin Mesylate

Name	Type	Description	Arm Group Labels	Other Names
Eribulin Mesylate	Drug	Eribulin mesylate IV infusion.	Eribulin Mesylate 1.23 mg

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Clinical Safety will be assessed by recording the adverse events (AEs) and serious AEs (SAEs) observed during the study period and its relation to the study medication. AE is defined as any untoward medical occurrence in a participant administered a treatment of medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, results in life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or results in a congenital anomaly/birth defect.	Baseline up to 30 days after last dose of study drug or at discontinuation (approximately up to 17 months)
Number of Participants with TEAEs Related to Laboratory Parameters	AE is defined as any untoward medical occurrence in a participant administered a treatment of medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, results in life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or results in a congenital anomaly/birth defect. TEAEs are defined as those events that started on or after the date and time of administration of the first dose of study drug and those events that were present prior to the administration of the first dose of study drug and increased in severity during the study.	Baseline up to 30 days after last dose of study drug or at discontinuation (approximately up to 17 months)

Secondary Outcomes

Measure	Description	Time Frame
Objective Tumor Response	Radiological confirmation of objective response rate (ORR) will be assessed by the Response Evaluation Criteria in Solid Tumors(RECIST)criteria version 1.1. The response would be assessed based on the four response parameters -complete response(CR), partial response(PR), stable disease(SD), progressive disease(PD).CR is defined as disappearance of all target lesions. PR is seen when there is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameters. When there is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameters since the treatment started then, the response is evaluated as SD.PD is seen when there is at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Participants with locally advanced or metastatic breast cancer.
Participants must have progressed after at least after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an Anthracycline and a Taxane unless participants who are not suitable for these treatments.
Participants must have documented disease progression within or on 6 months from their last anti-cancer therapy.
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (<=) 2.
Participants must have normal organ and marrow function as defined below:
- Absolute neutrophil count greater than (>) 1,500 per microliter (/mcL)
- Hemoglobin >10.0 gram per deciliter (g/dL)
- Platelets >100,000/mcl
- Serum total bilirubin less than (<) 1.5*upper limit of normal (ULN)
- Serum aspartate aminotransferase (AST) (Serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (Serum glutamic pyruvic transaminase [SGPT]) <3*ULN or <5*ULN in the presence of liver metastases
- Serum creatinine <1.5 mg/dL.
Females in reproductive age willing to follow adequate barrier contraceptive measures during the conduct of study.

Exclusion Criteria:

Hypersensitivity to the active substance or any of the excipients.
Participants who have received chemotherapy, radiation, or biological therapy within two weeks, or hormonal therapy within one week before study treatment start, or any investigational drug within four weeks before study treatment start.
Participants receiving any other investigational agents.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, recent myocardial infarction, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, or other comorbid condition that investigator believes may compromise participant's condition.
Participants requiring concurrent anti-cancer therapy during the study period.
Participants with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting study treatment.

Facility	Status	City	State	ZIP	Country	Contacts
HEMATO-ONCOLOGY CLINIC Vedanta Institute of Medical Sciences		Ahmedabad	Gujarat	380009	India
HealthCare Global Enterprises Ltd

ID	Term
D009371	Neoplasms by Site
D009369	Neoplasms
D001941	Breast Diseases
D012871	Skin Diseases
D017437	Skin and Connective Tissue Diseases